Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYRE vs HALO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HALO Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

HALO Overall Winner 6-Pillar Tally: SYRE 0 – 6 HALO Matrix Metrics: SYRE 2 – 8 HALO

As of Nov 16, 2026, Halozyme Therapeutics, Inc. (HALO) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas HALO carries 59.9/100 (HOLD) at $97.43 (9.5x Forward P/E, 56.7% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYRE vs HALO
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 56.6 · SMA20: $98.90 · SMA50: $91.75
HALO NASDAQ Head-to-Head Winner
Halozyme Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$97.43
-2.83% 1D
Market Cap $11.5B
TTM Revenue $1.80B
Forward P/E 9.5x
Beta / 30D Vol 0.57β · 59% Vol
Unified Composite Score
59.9 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 70.0 Mom 55.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 25
RSI-14: 25.2 · SMA20: $118.48 · SMA50: $114.33

6-Pillar Scorecard Institutional Category Breakdown (SYRE 0 – 6 HALO)

Columns: Metric · SYRE · HALO
1. Valuation Multiples HALO
Forward P/E N/M 9.5x
Trailing P/E N/M 25.2x
PEG Ratio N/M N/M
EV / Revenue N/M 7.6x
2. Growth & Scale HALO
Revenue Growth (YoY) +0.0% +39.2%
Earnings Growth (YoY) -99.7% +40.6%
TTM Revenue (USD) N/A $1.80B
Market Cap $9.8B $11.5B
3. Profitability & Quality HALO
Gross Margin N/A 76.0%
Operating Margin 0.0% 56.7%
Net Profit Margin 0.0% 26.9%
Return on Equity (ROE) -35.0% 216.4%
4. Balance Sheet & Cash Flow HALO
Cash Generation (TTM) N/A $598M
Cash Flow Margin N/A 33.2%
Net Cash / Leverage $10.06 Book/Sh · -35.0% ROE $2.22B Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HALO
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 87.9% (10th %ile) 39.7% (26th %ile)
Put/Call OI Skew N/A 0.36x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat HALO
OpEx & R&D Intensity N/A 19.3% of Rev ($348M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYRE (2) vs HALO (8)
Institutional Metric SYRE HALO Criterion Row Edge
Market Capitalization
Scale
$9.8B $11.5B Larger Scale HALO
Trailing P/E Ratio
Valuation
N/M 25.2x Lower Multiple HALO
Forward P/E Ratio
Valuation
N/M 9.5x Lower Multiple HALO
Revenue Growth (YoY)
Growth
+0.0% +39.2% Higher Growth HALO
Operating Margin (TTM)
Profitability
0.0% 56.7% Higher Margin HALO
Net Profit Margin
Profitability
0.0% 26.9% Higher Margin HALO
Return on Equity (ROE)
Capital Efficiency
-35.0% 216.4% Higher ROE HALO
52-Week Range Position
Momentum
88% ($22–$111) 50% ($61–$134) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
1.75β · 59% Vol 0.57β · 59% Vol Lower Realized Risk SYRE
Unified Institutional Score
Composite Signal
36.1 / 100 (SELL) 59.9 / 100 (HOLD) Higher Composite HALO
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.80B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 76.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 7.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($10.06 Book/Sh · -35.0% ROE) $598M ($2.22B Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +45.14 pp
SYRE: +25.11% · HALO: -20.03%
3M Horizon HALO +0.18 pp
SYRE: -7.29% · HALO: -7.11%
6M Horizon HALO +1.83 pp
SYRE: +42.64% · HALO: +44.47%
1Y Horizon SYRE +304.88 pp
SYRE: +341.74% · HALO: +36.86%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs HALO. Trailing 12-month operating profitability (SYRE 0.0% vs HALO 56.7%) and valuation multiples (SYRE N/M vs HALO 9.5x Forward P/E) are benchmarked directly in Pillar 4 below.

SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M
HALO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.80B
Gross Margin76.0%
Op. Margin56.7%
ROE / Fwd P/E216.4% · 9.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HALO CONSOLIDATION
58d in phase · OBV DISTRIBUTION
Current IV 39.7%
IV Percentile 26th %ile
Put/Call OI Skew 0.36x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact HALO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
HALO Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $11.5B market capitalization and 56.7% operating margin.
OpEx & R&D Reinvestment 19.3% of Rev ($348M)
90D Engineering Disclosures 0 Published

Investor FAQ SYRE vs HALO Key Questions & Quantitative Answers

As of Nov 16, 2026, Halozyme Therapeutics, Inc. (HALO) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas HALO carries 59.9/100 (HOLD) at $97.43 (9.5x Forward P/E, 56.7% operating margin). Technically, SYRE sits in a Neutral phase (RSI 56.6, UNCLASSIFIED options structure) and HALO sits in a Neutral phase (RSI 25.2, CONSOLIDATION options structure).

HALO leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with HALO at +39.2% YoY revenue growth and +40.6% YoY earnings growth on $1.80B TTM revenue (76.0% gross margin, 56.7% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus $1.80B for HALO. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus 19.3% of Rev ($348M) (0 disclosures) for HALO.

HALO screens cheaper on headline valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas HALO trades at 9.5x Forward P/E, 25.2x Trailing P/E, N/M PEG, and 7.6x EV/Revenue (33.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus HALO (216.4% ROE) capital efficiency.

In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk). By comparison, HALO carries 39.7% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.36x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.57β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.